Summary#
Bill 125, the Justice for Victims of Occupational Disease Act, 2022, would amend Ontario’s Workplace Safety and Insurance Act, 1997. Its stated goal is to change how occupational diseases are assessed and how substances linked to cancer are added to disease schedules.
- For deciding whether a health condition is an occupational disease, employment would have to be a “significant contributing factor”: more likely than not, and more than trifling or speculative. It would not have to be the sole, main or largest cause.
- Decision-makers could consider scientific information and information about work-related exposures, but could not use that information as a substitute for deciding a worker’s entitlement to benefits.
- All of a worker’s exposures would be presumed to add together, unless evidence of a synergistic effect (where combined exposures interact) rebuts that presumption. A higher rate of a disease in the worker’s workplace than in the community would be presumed to be evidence that the disease occurred because of the nature of the work.
- The Workplace Safety and Insurance Board (WSIB) would have to review the International Agency for Research on Cancer’s Group 1 and Group 2A lists at least annually.
- For certain Group 1 substances, the WSIB would have to ensure the substance is included in Schedule 3 and considered for Schedule 4. For certain Group 2A substances, it would have to ensure inclusion in Schedule 3, or, if the Board determines that inclusion is not possible, develop a policy after consulting workers, their representatives, employers and their representatives.
What it means for you#
- Workers with occupational-disease claims: The proposed rules would guide decisions about whether work contributed to a condition. They would not make every claim eligible for benefits automatically.
- Workers, employers and their representatives: They would be consulted if the WSIB determines that a Group 2A substance cannot be included in Schedule 3 and develops a policy about it.
- The WSIB: It would have new annual review and follow-up duties. The bill does not set out a claim application process, decision timelines, or appeal rules.
- The public: The bill would not itself create a new agency, tax, fine or front-line service.
Money#
No publicly available information on the bill’s cost is included in the supplied material.
- The WSIB would have to carry out annual reviews and, in some cases, develop policies and consult named groups. The bill gives no staffing or cost estimate.
- The bill does not specify new spending, fees, savings or revenue.
What is unclear#
- The supplied material does not include the current Act or its schedules. I could not verify how the proposed tests compare with current claim rules, or what substances and diseases are already listed.
- The bill does not explain how the WSIB would assess evidence, apply the exposure presumption, or decide that a Group 2A substance cannot be included in Schedule 3.
- It does not set out how consultations would work or how the resulting policies would affect individual claims.
- The bill says it would come into force on Royal Assent. The supplied material does not state whether it received Royal Assent. No publicly available information.
Case for#
- The bill appears intended to clarify when work counts as a significant cause of an occupational disease, including when other causes may also have contributed.
- Considering all exposures together could better reflect cases involving more than one workplace exposure.
- Annual reviews could help keep the disease schedules up to date with the named international cancer classifications.
- The higher workplace disease-rate presumption could make relevant workplace evidence count in claim decisions.
Case against#
- One concern is that the bill sets new evidentiary presumptions but does not explain how they would work in practice or how they interact with current rules.
- The terms “significant contributing factor” and “synergistic effect” may leave difficult judgment calls; the bill does not provide a detailed decision process.
- The bill gives the WSIB annual review and follow-up duties but does not specify resources, timelines for schedule changes, or oversight of the process.
- For Group 2A substances, the fallback is a WSIB policy rather than required inclusion in Schedule 3, leaving the outcome dependent on the Board’s determination.